RenalytixAI Announces Launch of Global Offering and Application to List on the Nasdaq Global Market

NEW YORK, July 13, 2020 /PRNewswire/ — Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced the commencement of an underwritten offering of 11,000,000 of its ordinary shares, which includes a registered public offering of ordinary shares in the form of American Depositary Shares (“ADSs“), each representing two ordinary shares, in the United States and a concurrent private placement of ordinary shares in Europe and other countries outside of the United States (together, the “Global Offering“). In addition, RenalytixAI intends to grant the underwriters a 30-day option to purchase additional ADSs in an aggregate amount of up to 15% of the total number of ADSs proposed to be sold in the Global Offering. Investors other than qualified investors under applicable law will not be eligible to participate in the ordinary share private placement. All ADSs and ordinary shares to be sold in the Global Offering will be sold by RenalytixAI.

RenalytixAI has applied to have its ADSs listed on the Nasdaq Global Market (“Nasdaq“) under the symbol “RNLX”. RenalytixAI’s ordinary shares are admitted to trading on the AIM market of London Stock Exchange plc (“AIM“) under the symbol “RENX”. Application will be made for the new ordinary shares to be issued at the closing of the Global Offering to be admitted to trading on AIM. The Company will maintain its AIM listing alongside the Nasdaq dual-listing.

J.P. Morgan and Stifel are acting as joint global coordinators and joint book-running managers for the Global Offering.

The Global Offering will be made only by means of a prospectus. Copies of the preliminary prospectus relating to and describing the terms of the Global Offering may be obtained from the offices of J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by telephone at +1 (866) 803-9204, or by e-mail at or from Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at +1 (415) 364-2720 or by email at

A registration statement relating to these securities has been filed with the U.S. Securities and Exchange Commission, but has not yet become effective. These securities may not be sold, nor may offers to buy these securities be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

For further information, please contact:

Renalytix AI plc

James McCullough, CEO

Via Walbrook PR


Stifel (Nominated Adviser, Joint Global Coordinator and Joint Bookrunner)

Tel: 020 7710 7600

Alex Price / Nicholas Moore 


Walbrook PR Limited

Tel: 020 7933 8780 or

Paul McManus / Lianne Cawthorne

Mob: 07980 541 893 / 07584 391 303

The person responsible for arranging the release of this announcement on behalf of the Company is James McCullough, CEO of Renalytix AI plc.

Forward-Looking Statements
Certain statements made in this press release are forward-looking statements including with respect to the Global Offering and the creation of a trading market for ADSs representing the Company’s ordinary shares in the United States. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including if the Company’s registration statement is not declared effective by the SEC, if Nasdaq fails to approve the Company’s ADS listing application or if there are adverse market or economic conditions. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this press release. The forward-looking statements made in this press release relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

For readers in the European Economic Area (“EEA”) and the United Kingdom
In any EEA member state and the United Kingdom, this communication is only addressed to and directed at qualified investors in that member state and the United Kingdom within the meaning of the Prospectus Regulation. The term “Prospectus Regulation” means Regulation (EU) 2017/1129.

For readers in the United Kingdom
There will be no offer of ADSs or ordinary shares to the public in the United Kingdom.

This communication, in so far as it constitutes an invitation or inducement to enter into investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 as amended (“FSMA”)) in connection with the securities which are the subject of the offering described in this press release or otherwise, is being directed only at (i) persons who are outside the United Kingdom or (ii) persons who have professional experience in matters relating to investments who fall within Article 19(5) (“Investment professionals”) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) certain high value persons and entities who fall within Article 49(2)(a) to (d) (“High net worth companies, unincorporated associations etc.”) of the Order; or (iv) any other person to whom it may lawfully be communicated (all such persons in (i) to (iv) together being referred to as “relevant persons”). The ADSs or ordinary shares offered in the Global Offering are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such ADSs or ordinary shares will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. This communication does not contain an offer or constitute any part of an offer to the public within the meaning of sections 85 and 102B of FSMA or otherwise.

This announcement contains inside information.

Not for release, publication or distribution, in whole or in part, in or into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

SOURCE RenalytixAI